The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in head and neck and colorectal cancers. In a recent study, Yonesaka et al. uncovered a new mechanism of cetuximab resistance mediated by increased ERBB2 signaling via amplification of ERBB2 or increased levels of the ERBB3/ERBB4 ligand heregulin
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-targeting drug cetu...
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell ...
The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the impressiv...
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in h...
The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cance...
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety...
Abstract Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor ...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
Epidermal Growth Factor Receptor (EGFR) activates a robust signalling network to which colon cancer ...
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodie...
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck squamous cell carci...
EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation,...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
The epidermal growth factor receptor (EGFR) drives tumor growth in a subset of human epithelial carc...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-targeting drug cetu...
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell ...
The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the impressiv...
The EGFR-directed antibody cetuximab has proven, albeit modest, clinical benefit as monotherapy in h...
The EGFR-targeted antibodies cetuximab and panitumumab are used to treat metastatic colorectal cance...
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a variety...
Abstract Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor ...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
Epidermal Growth Factor Receptor (EGFR) activates a robust signalling network to which colon cancer ...
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodie...
The epidermal growth factor receptor (EGFR) is widely expressed in head and neck squamous cell carci...
EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation,...
EGFR is frequently overexpressed in head and neck squamous cell cancer (HNSCC). Cetuximab is a monoc...
The epidermal growth factor receptor (EGFR) drives tumor growth in a subset of human epithelial carc...
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head and neck squa...
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-targeting drug cetu...
Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell ...
The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the impressiv...
DOI
Add to ORKG